We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Cambridge Cognition Holdings Plc | LSE:COG | London | Ordinary Share | GB00B8DV9647 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -0.50 | -1.45% | 34.00 | 11,221 | 14:52:12 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 33.00 | 35.00 | 34.50 | 34.00 | 34.50 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 13.52M | -3.51M | -0.0836 | -4.07 | 14.47M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 14:52:13 | O | 4,705 | 33.20 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 12/9/2024 | 12:38 | UK RNS | Cambridge Cognition Holdings PLC Directorate change |
| 22/8/2024 | 13:42 | ALNC |  Cambridge Cognition narrows loss and slashes costs in first half |
| 22/8/2024 | 07:00 | UK RNS | Cambridge Cognition Holdings PLC Interim Results |
| 20/8/2024 | 07:00 | UK RNS | Cambridge Cognition Holdings PLC Notice of Results |
| 12/8/2024 | 12:15 | UK RNS | Cambridge Cognition Holdings PLC Holding(s) in Company |
| 26/7/2024 | 07:00 | UK RNS | Cambridge Cognition Holdings PLC Issue of Equity and Total Voting Rights |
| 23/7/2024 | 16:46 | ALNC | EARNINGS AND TRADING: James Cropper posts loss; Arbuthnot profit falls |
| 23/7/2024 | 07:00 | UK RNS | Cambridge Cognition Holdings PLC Trading Update & Board Change |
| 11/7/2024 | 18:13 | ALNC | EARNINGS AND TRADING: MJ Gleeson optimistic; Hornby annual profit down |
| 11/7/2024 | 07:00 | UK RNS | Cambridge Cognition Holdings PLC Cambridge Cognition secures Innovate UK.. |
Cambridge Cognition (COG) Share Charts1 Year Cambridge Cognition Chart |
|
1 Month Cambridge Cognition Chart |
Intraday Cambridge Cognition Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 27/9/2024 | 01:35 | Cambridge Cognition Holdings (COG) | 728 |
| 02/2/2023 | 20:18 | Dementia - Computerised Neuropsychological Testing | 189 |
| 30/4/2019 | 22:22 | Cambridge Cognition at UK Investor Show | 1 |
| 02/9/2017 | 15:05 | COG with Charts & News | 63 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-10-08 13:52:14 | 33.20 | 4,705 | 1,562.06 | O |
| 2024-10-08 13:52:01 | 34.00 | 6,500 | 2,210.00 | O |
| 2024-10-08 11:33:47 | 34.00 | 5 | 1.70 | O |
| 2024-10-08 11:33:47 | 34.00 | 11 | 3.74 | O |
| Top Posts |
|---|
Posted at 08/10/2024 09:20 by Cambridge Cognition Daily Update Cambridge Cognition Holdings Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker COG. The last closing price for Cambridge Cognition was 34.50p.Cambridge Cognition currently has 41,940,413 shares in issue. The market capitalisation of Cambridge Cognition is £14,259,740. Cambridge Cognition has a price to earnings ratio (PE ratio) of -4.07. This morning COG shares opened at 34.50p |
Posted at 05/9/2024 13:33 by 40 fathoms This was posted today, no RNS but interesting nonetheless.Don't seem able to post the link, so here is a copy of the text "US patient recruitment firm Splash Clinical has teamed up with UK-based digital brain health services provider Cambridge Cognition (COG) to help sponsors find people to participate in central nervous system (CNS)-focused drug trials. The new partnership – financial terms of which were not disclosed – will see Splash utilize COG’s pre-screening technology to assess potential participants for studies focusing on CNS indications. In a press statement, Splash CEO Matt Teuteberg, said, “By integrating their assessment tools into our platform, we will increase our efficiency in finding the right patients for clinical trials. This partnership will save time and resources for our clients and ultimately make treatments available for patients faster.” CNS recruitment Finding the right patients to take part in drug research is always difficult, nonetheless of the disease involved. Recruiting for trials focusing on neurological disorders is a particular challenge. For example, a 2023 study in the journal Innovations in Clinical Neuroscience suggested the lack of information about CNS patients combined with the nature of the diseases themselves are the issue. “In contrast to other therapeutic areas, such as oncology or cardiovascular diseases, there are no large clinical research networks for CNS, making it more difficult to efficiently reach patients in their care setting. There are also challenges associated with CNS disorders themselves that are not relevant to other therapeutic areas … Thus, the timely recruitment and retention of the right and representative patients is a challenge for CNS clinical trials.” COG’s technology is designed to address such difficulties. The system consists of an online cognitive assessment portal that gathers and processes data from potential study participants. According to the firm, the assessment, which takes around ten minutes, reduces screening failures and increases the quality of patients entering the trial. Splash said that, in combination with its own suite or recruitment tools, the new tech will help it reach a broader population while maintaining high-quality standards. Liam Kaufman, Cambridge Cognition’s vice president of clinical sciences, emphasized the potential benefits of the collaboration, explaining “They’ve got a great recruitment platform and a solid track record in recruitment. Our tools complement their process perfectly. Our goal is to make it easier for researchers to find the right participants for their CNS trials. It’s a win-win for everyone involved.” She added that during a pilot collaboration completed last year, COG’s software helped filter in hard-to-find patients with early Alzheimer’s symptoms. News of the collaboration comes a few months after the Michael J. Fox Foundation began using COG’s technology to identify the cognitive profile of Parkinson’s Disease patients as part of an effort to identify biomarkers – and potential druggable targets – for the condition. |
Posted at 31/8/2024 10:25 by earwacks I remember a few years back a director of an aim company telling me his solicitor advised reporting as a little to the market as possible and preferably nothing at all. Some seem to have turned this in to an absolute art form, others seem to court the market too much. You only have to look at the top holders list in COG to see they are not too bothered with investor relations with PIs. I seem to remember Vox markets or Paul Scot saying they hoped to do an interview with Cog. Presumably too busy or not keen. It does seem that private investor’s frequent trades can mess with the share price on very low volumes. I guess this can become an issue with small companies when trying to raise finance |
Posted at 24/8/2024 12:03 by earwacks @40Fathoms. End of September when the loan note news was made public the share price was @92p. By the time they issued the warrants on October 5th the share price had dropped to low 70s. I think the key is what date the execution of the loan took place. Unless it was written in stone about the 91p looks like the 5 day average weighting was around 74 p. The only thing definite in the September RNS is that the warrants will equate to £540000. About £125000 difference, unfortunate but in the grand scheme maybe not too bad. Probably took them by surprise, as they thought the loan was the better fund raise option. Then all the delays kicked in and we are where we are. I wouldn’t have bought anymore if not for the drop, so in the long run if it works out will be in a better position. Looking back on the mysterious ‘ existing investor’ they took 955000 shares which is about £325,000. So maybe not Claret as I don’t recall them having any shares. Hoping this is one of those IHT free stock. Trouble is good aim companies keep getting taken over, so not a very reliable plan long term! |
Posted at 22/8/2024 15:43 by nchanning If they really hit these revenue forecasts of 14m and 16m for 2025 , 80 % gross margins , growing end markets and already modestly profitable this share price could go ballistic . Still a lot of work to do in this H2 after just 5.6m in H1 . Neither the company's own results narrative nor the broker note convinced me this is in the bag . Still only a small position for me would back up the truck if they start executing |
Posted at 25/6/2024 01:04 by 40 fathoms @bedford1976 - They are already international in their reach and the significant percentage of their revenue is generated outside of the UK. This is mainly done directly and not via partnership. That said they do have an exclusive partnership for the China market and they have talked in the past about the possibility of non exclusive partnerships with CROs and certain Pharma. This aside I think most likely partnerships are likely to be technology based rather than geographical. The recent ActiGraph partnership being a good example. The other areas they have suggested they would look to partnership is for the healthcare and diagnostics opportunity.@Yump - For the potential size and scope of larger contracts you can look at Cogstate listed in Australia. They have a contracted order book in excess of US$100 million and in the last 3 or 4 years they have signed 1 contract in excess of US$10 million and one in excess of US$ 25 million. The larger one was for Eli Lilly and they worked on the Donanamab Phase III trial, which are currently with the FDA for approval. Both of these contracts were for providing work in to Phase III AD trials (AD is Cogstate's core area. About half of these amounts is accounted for by the provision of raters and rater training, which COG does not provide, so these numbers would need to be cut by 50% to get a sense of what a very large contract for COG might look like. In the next 24/36 months it is a certainty that we will see numerous contracts in excess of GBP 3 million and maybe one or two that tops GBP 5 million. |
Posted at 24/6/2024 18:09 by yump Will probably buy a smattering of shares. Its quite interesting looking around for ex-hyped stuff after disillusionment has set in with the share price, despite businesses that are actually increasing revenues. They get the same treatment as the ones that don't have any revenue trend, or a reducing one.Not a fan of brokers targets - they don't have their own money invested and no way buying because someone else has. I think I saw that COG made a statement a while ago that they were expecting to grow faster than the overall market - think it was in a fairly recent report. Tricky part is knowing the best time to buy. The p/e ratios are pretty irrelevant early on, often looking very high, but that doesn't matter if there are profit jumps in a couple of years. |
Posted at 30/5/2024 15:13 by bedford1976 Comments here are spot on the company is moving towards healthy profitability with good gross margins, but why lose out on some great opportunities just because of tight cashflow.In a couple of years I am personally aiming for a share price of £2.00. I cannot find another company like Cambridge Cog on the AIM market in such a good niche market which is growing at 17% per annum. |
Posted at 29/5/2024 17:21 by cerrito I guess the reason there was no IMC type event or indeed ,as far as I can see , no announcement of the AGM was that they were working on the funding raise and the share price movement-or lack of it-suggests there was no news leakage.For me the price and the discount to the share price is par for the course even though this is not am emergency raise. Do not see myself going into the open offer as I have a sneaky feeling I will be able go pick up sub 40p in thr next month. |
Posted at 17/5/2024 13:55 by earwacks Vladim Alexandre , analyst who was with share price Angel has done a recent interview on this stock. He acknowledges the current difficulty in this sector but says a company like COG that once showed 25 per cent growth but still can do 7 percent in a tougher climate is the sign of a very strong company. What is strange is nobody seems to factor in any value of their 25 percent stake in Monument either. Plenty of positives.life science is a pretty nervous market at the moment and volatile, with companies like EKF(I own, Niox my biggest holding and Vrci and Renx which I don’t own yet. Cog, Niox and Ekf I like because they seem to have more control over what they do. The other two seem heavily reliant on what someone else might do for them. The share price fall here is a little unsettling as there appears no obvious reason for it in a market that looks to be getting a little stronger and more stable. |
Posted at 13/10/2023 04:42 by 40 fathoms This link is to an investor day video that was posted today by Cogstate to help investors understand the their cognitive digital trials business. The video is long, so it might something for the weekend viewing.Cogstate is a very similar company to CAMCOG. However, it is further advanced in its commercial development and has a much narrower focus, primarily on Alzheimer's (@70% of revenue) and rare diseases (@10% of revenue). At this point the companies are rarely in direct competition and for both of them their biggest competitors remain the providers of traditional pencil and paper tests. Just to give a sense of the potential size and scope of these markets last year Cogstate put out an estimate that despite being far in the lead in AD they still only had @17% of cognitive testing in the AD trials market. It is also worth noting that CAMCOG is involved with numerous early stage AD trials and will end up with a decent share of the AD market overtime. The video gives a very good overview of the cognitive testing business case and also the huge and deep moat that these companies are able to enjoy. It also shows very clearly how well CAMCOG is positioned in the cognitive trial services ecosystem. CAMCOG is far ahead, both in terms of its technology and the scope of services it is able to offer in to trials. It is also probably also worth mentioning that AD only represents about 15% of the total spend in CNS space. I hold both companies and it is clear that both will grow revenue significantly in the coming 3 or 4 years. However, for CAMCOG specifically we should understand it is about 3 or 4 years behind Cogstate in its move from R&D and validation to commercialisation. Cogstate clearly demonstrates the commercial path and revenue trajectory that we are on. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
